Health
Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer
Experienced medical executive advances to permanent role following successful leadership as Interim CMOSEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that it has confirmed the promotion of Mark Rubinstein, M.D., from Interim Chief Me
About this update from Achieve Life Sciences, Inc.
[{"type":"image","alt":"Achieve Life Sciences","displaySize":"","headline":null,"caption":"Achieve Life Sciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":269,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/f01e07053436b73353dd8f78efeb68ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Nz0ojNZV.4IpZgjbhcgTOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f01e07053436b73353dd8f78efeb68ec","width":269,"height":300}},"lazy":false},{"type":"text","content":"Experienced medical executive advances to permanent role following successful leadership as Interim CMO","length":103,"tagName":"p"},{"type":"text","content":"SEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that it has confirmed the promotion of Mark Rubinstein, M.D., from Interim Chief Medical Officer to Chief Medical Officer (CMO).","length":442,"tagName":"p"},{"type":"text","content":"Since Dr. Rubinstein began his tenure as Interim CMO in September 2025, the company has achieved significant clinical and regulatory milestones, and he co-authored the recent paper in Thorax of data demonstrating cytisinicline’s potential efficacy and tolerability for smoking cessation in individuals with COPD.","length":312,"tagName":"p"},{"type":"text","content":""Dr. Rubinstein has been an excellent addition to our leadership team during this pivotal period," said Rick Stewart, President and Chief Executive Officer of Achieve Life Sciences. "His reputation and expertise in nicotine cessation strengthens our medical leadership as we advance toward regulatory review. We are pleased to confirm his appointment to the permanent CMO role, and we're confident the team will continue to drive our progress forward."","length":476,"tagName":"p"},{"type":"text","content":"Dr. Rubinstein brings more than two decades of experience in clinical medicine, scientific research, and medical affairs leadership, with a strong focus on nicotine cessation and preventive medicine. Prior to joining Achieve as Head of Medical Affairs in October 2024, he served ...